PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 13, 2026Neuro-Oncology Pediatrics0 citations

An Analysis of PD1 Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13

View Full Paper
SRScott RaskinCincinnati Children's Hospital Medical CenterCYC. YangUniversity of FloridaTLTong LinSt. Jude Children's Research Hospital

Key Points

  • The study aims to understand the differences in immune activity among various pediatric malignant brain tumors.
  • Sampled 100 archived patient samples from four categories of pediatric malignant brain tumors.
  • Measured PD-1 and PD-L1 expression levels in tumor samples.
  • Conducted extensive immune profiling to analyze the immune landscape of the tumors.
  • Identified variations in PD-1 and PD-L1 expression across different tumor types.
  • Revealed distinct immune profiles that could influence patient treatment strategies.

Abstract

Lay Summary The Pediatric Brain Tumor Consortium Study, PBTC-N13, sampled 100 archived patient samples from four different pediatric, malignant brain tumor categories. Each sampled was tested for PD-1 and PD-L1 expression and then had more extensive immune profiling. This enables learning how the immune landscape differs among tumors in order to better understand the potential for individual tumor immune profiling to be considered in patient-directed care.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Raskin et al. (2026) studied this question.

synapsesocial.com/papers/69dc88d83afacbeac03ea884https://doi.org/10.1093/neuped/wuag020
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IMMU-79. An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N132025
  2. 2LBA-01. Tumor and systemic molecular / immune correlates and patient reported QOL in pediatric CNS and solid tumors treated with PD1 inhibition and conventional versus hypofractionated radiation on PNOC0132025
  3. 3HGG-09. Clinical Outcomes and Therapeutic Implications of Low TMB and PD-L1-Mutated Pediatric CNS Tumors: A Case Series2025
  4. 4Abstract 5467: Identification of possible new treatment options for rare pediatric CNS tumors using a panel of validated and characterized PDX models2024
  5. 5Abstract LB310: Single-cell transcriptomics and TCR clonality reveal a role for immunotherapy in pediatric brain tumors2024